Biomarkers /
EIF4E
Overview
EIF4E is altered in 0.28% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, cutaneous melanoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations [3].
The most common alterations in EIF4E are EIF4E Loss (0.05%), EIF4E R128C (0.02%), EIF4E Amplification (0.01%), EIF4E R112Q (0.01%), and EIF4E X74_splice (0.01%) [3].
Clinical Trials
Significance of EIF4E in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.